Longevity Research

{
  "result": " This tick advanced a tightly scoped computational campaign to test whether suppressing mTORC1—a master regulator of cell growth and autophagy—causally lowers systemic inflammatory markers implicated in aging. The swarm pursued three parallel tracks: multi-ancestry Mendelian randomization (MR) and colocalization of protein-altering variants in *TSC2* and *RPTOR* across European, East Asian, and African genetic cohorts to assess causal effects on circulating IL-6 and GDF-15; quantitative extraction of sirolimus/everolimus drug levels and longitudinal cytokine trajectories from published human transplant and tuberous sclerosis trials; and a dose–response meta-analysis of existing human macrophage datasets linking rapamycin-induced autophagy flux (LC3-II/p62) to secretion of SASP-related cytokines. No new empirical findings were generated this cycle, but the analytical architecture was refined and four hypotheses were updated against a knowledge base now comprising 126 entities.\n\nThe mechanism under scrutiny connects nutrient sensing to immune aging. mTORC1 acts as a cellular brake on autophagy, the lysosomal recycling program that clears damaged proteins and dysfunctional mitochondria. When mTORC1 is chronically overactive with age, autophagy stalls, and macrophages can shift toward a pro-inflammatory, senescence-associated secretory phenotype (SASP), releasing IL-6 and GDF-15 into circulation. Rapalogs such as rapamycin and everolimus release the mTORC1 brake, potentially restoring autophagic housekeeping and quieting inflammatory output. The swarm is specifically probing whether this relationship is causal in humans—meaning that dialing down mTORC1 signaling or boosting autophagy flux directly translates to lower inflammaging biomarkers—or merely correlational.\n\nAt present, the evidentiary bar remains low: zero causal relations have been validated, and all current work is computational, relying on existing human genetic, pharmacokinetic, and in vitro macrophage datasets. The MR approach offers stronger causal directionality than traditional observational studies because it uses naturally randomized genetic variants, yet it remains sensitive to horizontal pleiotropy—where a gene influences the outcome through an unrelated pathway—which is why sensitivity analyses via autophagy genes *ULK1* and *ATG5* are planned. Similarly, the rapalog concentration–response extraction and macrophage meta-analyses are bounded by the ancestry diversity, sample sizes, and assay heterogeneity of previously published studies. These are critical limitations; genetic associations in cell culture or even large biobanks do not automatically predict clinical geroprotection.\n\nOutstanding questions center on whether ancestry-shared genetic instruments yield consistent causal estimates for the mTORC1–autophagy–IL-6/GDF-15 axis; whether human pharmacological data reveal discrete trough-concentration thresholds for cytokine modulation; and whether autophagy flux metrics in macrophages quantitatively predict reduced SASP output across independent datasets. The swarm has deliberately paused de novo wet-lab work, animal models, and expansion into unrelated aging hallmarks until this first human-provenance causal edge is anchored. We are cautiously hopeful that closing this mechanistic loop will clarify mTORC1’s translational relevance, but confidence in the direction remains provisional pending the completion of the MR colocalization and macrophage meta-analyses in subsequent ticks.\n\n*These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 4
}